Table 1.
Treatment and challenge of CAR-T cell therapy in the treatment of solid tumors.
Clinical challenges | Strategy | Expected outcome |
---|---|---|
Lack of specific targets [44] | Designed an antigen-specific inhibitory CAR-T molecule and a dual target CAR-T cells [48, 94] | Achieving dynamic and safe regulation of CAR-T cells [49] |
CAR-T cell cannot effectively migrate and infiltrate tumor tissue [44] | Overexpression of HPSE in CAR-T cells can effectively degrade extracellular matrix and effectively infiltrate tumor tissue | Applied to solid tumor treatment [94] |
Effect of tumor microenvironment on CAR-T cell therapy [44] | Specific blocking of immune checkpoint inhibition [48, 49, 94] | Improving the therapeutic effect of CAR-T cells in solid tumor [48, 94] |
Tumor heterogeneity [52] | Expanding the scope of CAR-T cell therapy targeting tumor cells | Reduce tumor cells to immune response without immune response or low response to immune escape |